MX2017013669A - Composiciones para el tramiento del cancer. - Google Patents

Composiciones para el tramiento del cancer.

Info

Publication number
MX2017013669A
MX2017013669A MX2017013669A MX2017013669A MX2017013669A MX 2017013669 A MX2017013669 A MX 2017013669A MX 2017013669 A MX2017013669 A MX 2017013669A MX 2017013669 A MX2017013669 A MX 2017013669A MX 2017013669 A MX2017013669 A MX 2017013669A
Authority
MX
Mexico
Prior art keywords
compositions
cancer
treatment
amd3100
administering
Prior art date
Application number
MX2017013669A
Other languages
English (en)
Inventor
C Poznansky Mark
reeves Patrick
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2017013669A publication Critical patent/MX2017013669A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención descrita en la presente está relacionada a composiciones para tratar cáncer en un paciente, o una cólula tumoral, al administrar una cantidad efectiva de AMD3100 a lo largo de un periodo de tiempo.
MX2017013669A 2015-04-24 2016-04-25 Composiciones para el tramiento del cancer. MX2017013669A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152815P 2015-04-24 2015-04-24
US201562152824P 2015-04-25 2015-04-25
PCT/US2016/029258 WO2016172730A1 (en) 2015-04-24 2016-04-25 Compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2017013669A true MX2017013669A (es) 2018-07-06

Family

ID=57144335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013669A MX2017013669A (es) 2015-04-24 2016-04-25 Composiciones para el tramiento del cancer.

Country Status (11)

Country Link
US (1) US20180117005A1 (es)
EP (1) EP3285763A4 (es)
JP (1) JP2018514586A (es)
KR (1) KR20180035733A (es)
CN (1) CN108024991A (es)
AU (1) AU2016253153A1 (es)
CA (1) CA2983762A1 (es)
IL (1) IL255167A0 (es)
MX (1) MX2017013669A (es)
RU (1) RU2017140779A (es)
WO (1) WO2016172730A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049232A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Compositions having anti-fugetactic properties for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AU2006304883A1 (en) * 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
US9198597B2 (en) * 2008-05-22 2015-12-01 Christopher Duma Leading-edge cancer treatment
US9155723B2 (en) * 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
CN108024991A (zh) 2018-05-11
JP2018514586A (ja) 2018-06-07
IL255167A0 (en) 2017-12-31
EP3285763A4 (en) 2018-12-05
EP3285763A1 (en) 2018-02-28
RU2017140779A (ru) 2019-05-24
AU2016253153A1 (en) 2017-12-07
KR20180035733A (ko) 2018-04-06
WO2016172730A1 (en) 2016-10-27
CA2983762A1 (en) 2016-10-27
US20180117005A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
MX2023008693A (es) Polinucleotidos moduladores.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MY178821A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX379622B (es) Compuestos espirociclicos
MX2017000306A (es) Metodos para tratar hipotension.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2018011379A (es) Tratamiento del prurito uremico.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
IN2013MU03118A (es)
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms